Business
Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit
LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the
About this update from Virax Biolabs Group Limited
[{"type":"text","content":"LONDON, March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (\"Virax\" or the \"Company\") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of an Avian Influenza A Virus (\"AIV\") real-time PCR test kit to markets accepting the CE mark, namely the European Union. The test kit is for the detection and differentiation of ribonucleic acid from AIV and the H5, H7 and H9 subtypes, including the H5N1 strain currently spreading in Europe.\n\n \n \n \n \n \n \n\n \nThe test kit is for use in laboratory settings and can help healthcare professionals accurately identify an AIV infection. It also serves as a valuable initial screening test for individuals that have been exposed to AIV infected livestock or a high-risk environment. The specialized diagnostic kit can be found by contacting the company's sales representatives. \nHuman infections with AIV have occurred in many countries, predominately after exposure to infected poultry or virus-contaminated environments. Six main hemagglutinin subtypes of bird flu viruses have infected people and have resulted in mild-to-severe illness with a wide range of symptoms and complications. These six subtypes include H3, H5, H6, H7, H9, and H10 viruses. Among these, H5N1 and H7N9 viruses have caused the majority of infections which occur in humans.\nVirax's Chairman of the Board of Directors and Chief Executive Officer, James Foster commented, \"We continue to expand our ViraxClear distribution platform to bring test solutions to a widening range of viral threats. With a real-time PCR test kit poised to accurately and reliably detect AIV, including the deadly H5N1 strain, we expect to facilitate rapid and potentially life-saving interventions especially in vulnerable jurisdictions.\"\nAbout Virax Biolabs Group Limited\nFounded in 2013, Virax Biolabs Group Limited is an innovative diagnostics company focused on the prevention, detection and diagnosis of viral diseases, with a particular interest in the field of immunology.\nIn addition to distributing an array of viral test kits in unique geographies, Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platfor...